About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
  Fact Sheet
  Vision Mission Values
  CSR Policy
  EHS Policy
  Biocon in Malaysia
  Key Facts

Subsidiary Companies

The Company has formulated a policy for determining ‘material’ subsidiaries pursuant to the provisions of the Listing Agreement. The said policy is available at the Company website http://www.jkzddm.com/docs/PolicyDocument_MaterialSubsidiary.pdf

The Company has 8 subsidiaries and 2 step down subsidiaries as on March 31, 2016. Biocon FZ-LLC, a wholly owned subsidiary was incorporated on June 16, 2015 in Dubai. Biocon Biologics Limited, a wholly owned subsidiary was incorporated on March 2, 2016 in the United Kingdom. Biocon Pharma Inc, was incorporated on July 27, 2015 in the United States of America as a wholly owned subsidiary of Biocon Pharma Limited.

fun88 International Limited

fun88 International Limited (“fun88”) is one of India’s leading contract research organisations offering a suite of integrated, end-to-end discovery and development services for novel molecular entities (NMEs) across industrial sectors including pharmaceutical, fun88官网, and biotechnology amongst others. fun88 helps its clients in conducting discovery (from hit to candidate selection), development (including pre-clinical and clinical studies, analytical and bio-analytical evaluation, formulation development and stability studies) and pilot manufacturing (scale-up, pre-clinical and clinical supplies) each with distinctive economic advantage. Unlike the traditional business models, these services are offered through flexible business models ranging from a full-time equivalent (“FTE”) to a fee-for-service (“FFS”) model or a combination customized on the client’s specific requirement.

On August 11, 2015 fun88’s shares were listed on the NSE and the BSE after a successful Initial Public Offering (IPO) through an offer for sale by the Company.
Biocon Research Limited
Biocon Research Limited (BRL), a 100% subsidiary of the Company, undertakes discovery and development research work in biologics and provides scientific support for various development programmes of the group.

BRL’s current business is largely directed towards the R&D services for Monoclonal antibody molecules and Proteins (mAbs), insulin Tregopil (formally referred to as IN-105) and other insulin products on behalf of other group companies. The research programs undertaken by BRL have made significant inroads to the next level of global clinical trials. During the year, BRL licensed the ex-India development and commercialisation rights of its existing mAbs portfolio to Biocon Biologics Limited (‘BUK’). BRL continues to hold 0.93% shareholding in fun88.

Biocon Pharma Limited
Biocon Pharma Limited (“BPL”) is a wholly owned subsidiary of the Company. BPL would be engaged in the development and manufacture of generic formulations for sale in global markets, especially opportunities in US/EU. BPL is in the process of setting up its formulations manufacturing facility for oral solid dosages at Biocon SEZ, Bengaluru.

Biocon Academy
Biocon Academy spearheads Biocon’s CSR initiatives in the technical/professional education segment. The academy was established as a Centre of Excellence for Advanced Learning in Biosciences in 2014. Biocon Academy leverages rich industry experience of Biocon and subject matter expertise of international Education Partners such as Keck Graduate Institute of Claremont, California (USA). The academy is dedicated exclusively to industry oriented biosciences education. The programs offered by
the academy aim to empower the Biotechnology and Engineering graduates with advanced learning and industrial proficiency through job-skills development essential to build a promising career in the Biotech industry.

Biocon SA

Biocon SA, a wholly owned subsidiary of the Company, is primarily engaged in the business of development and commercialization of generic recombinant human insulin and its analogues for global markets under various internal as well as partnered programs. Biocon SA also holds the marketing rights for the group’s insulin portfolio.

Biocon SA is also in the business of identifying and developing other novel molecules into commercial products or licensable assets through strategic partnerships.

Biocon SDN. BHD
Biocon SDN. BHD., Malaysia is a step down subsidiary of the Company, wholly owned by BUK. Biocon SDN. BHD. was established with an objective to set up the group’s first overseas manufacturing facility at Malaysia. It is located within BioXcell, a biotechnology park in Nusajaya, Johor, which is being promoted by the Malaysian
Government. The first phase of the facility, designed to manufacture recombinant human insulin and insulin analogs has been commissioned and a series of operational processes - scale up, validation, and stability activities were performed in FY 2015-16. The manufacturing facility received local cGMP certification from the National Pharmaceutical Control Bureau, Malaysia and the plant is currently undergoing a series of validation activities to certify its operational efficiency.

Biocon SDN BHD will seek approvals from leading regulatory agencies across the globe for marketing its products in various RoW during FY’17. Approval from the developed markets are expected in the later years. The Malaysian facility is expected to start commercial operations in the second half of FY17.

NeoBiocon FZ LLC
Neo Biocon FZ LLC (“NeoBiocon”), a 51% owned subsidiary of the Company is a research and marketing pharmaceutical company, which was incorporated in January 2008. Operating out of Dubai and Abu Dhabi, NeoBiocon helps us reach out to the Middle East and GCC with our veritable portfolio of quality small molecule drugs.

Biocon FZ -LLC
Biocon FZ LLC is a wholly owned subsidiary of the Company based in Dubai. Incorporated in June 2015, Biocon FZ LLC has been established as a marketing entity for pharmaceutical products to target markets in the Middle East and GCC.

Biocon Biologics Limited
Biocon Biologics Limited (“BUK”) is a wholly owned subsidiary of the Company. Incorporated in the United Kingdom in March 2016, BUK will house Biocon’s biosimilar biologics business. During the year, BUK acquired the shareholding of Biocon SDN. BHD. from Biocon SA and the Company, making Biocon SDN. BHD. a wholly owned
subsidiary of BUK.

Biocon Pharma Inc.
Biocon Pharma, Inc. (“BPI”) is a wholly owned subsidiary of Biocon Pharma Limited was incorporated in July 2015 in the United States of America. BPI would be engaged in commercialization of generic formulations in the United States.



Mylan & Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency

Biocon's Insulin Glargine Launched in Japan

Biocon, Quark Announce Initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India

Mylan and Biocon to Present Phase 3 Trastuzumab Biosimilar Data at the American Society of Clinical Oncology (ASCO) Annual Meeting

Biocon's Insulin Glargine Receives Regulatory Approval in Japan

Biocon Announced Data from Key Studies for Insulin Tregopil

Biocon Gets its First Generic Formulation Approval in EU; On Track to Launch Rosuvastatin Tablets in FY17

Biocon Inks Co-Development & Commercialization Agreement with Lab PiSA for rh- Insulin in USA

Biocon's Insulin Glargine Receives Regulatory Approval in Japan


Biocon Introduces CIMIVIR-L™ for Hepatitis-C in India

NeoBiocon Partners with Novartis to offer Vildagliptin for Diabetics in UAE

Biocon Foundation Recognized for Outstanding Contribution to Public Health by WHO -India

Biocon Strengthens its Presence in Mexico; Receives Approval for Insulin Glargine through its partner PiSA Farmaceutica

Biocon's CRO Arm fun88 Seeks Approval for IPO, Files DRHP; Offer allows Biocon to monetize its shareholding in fun88

Biocon-Mylan Programs Make Progress: PEG-G-CSF and Adalimumab enter Phase 3 clinical trials; Patient recruitment for one Insulin Glargine Phase 3 study completed

Biocon's Biosimilars Programs Make Progress; One of the Largest Generic Insulin Analogs and Biosimilars Portfolio in Advanced Stages of Development

Biocon's CRO Arm fun88 Lists on BSE and NSE; Valued at $1 billion on Market Debut

Biocon Inaugurates World Class Devices Facility in Bangalore & Introduces Basalog One in India

Biocon is the Only Asian Company to be Ranked Among Top 20 Global Biotech Employers for 2015


Biocon has been conferred with the Sir J C Bose Memorial Award – 2013 (Institutional category) by Indian Science Monitor (ISM) for its contribution in the field of Biotechnology, with special reference to the launch of ALZUMAb (Itolizumab)

Biocon introduced CANMAb - Trastuzumab for Treating Breast Cancer in India

fun88, a subsidiary of Biocon Group, in collaboration with Baxter sets up a dedicated Research and Development Center at Biocon Park

Silver Leaf Oak (Mauritius) Limited, an investment vehicle advised by India Value Fund Advisors acquires a minority 10% stake in fun88 International Limited, Biocon's Research Services subsidiary. Silver Leaf will acquire the stake from Biocon Research Limited, a wholly owned subsidiary of Biocon Limited at a valuation of Rs.3800 Crore


Biocon received Marketing Authorization from the Drugs Controller General of India (DCGI) for its Novel Biologic Itolizumab, anti CD6 molecule, for the treatment of chronic plaque Psoriasis

Biocon enhances Partnership with Mylan through Strategic Collaboration for Insulin Products

Biocon Delivers a Healthy Growth of 22% driven by strong traction in Biopharma

Biocon Launched ALZUMAb- a 'First in Class' Novel Biologic Treatment for Psoriasis Patients in India

Biocon Partnered with CytoSorbents to Market CytoSorb® - A 'First-in-Class' Therapy for Sepsis Management

Biocon Ranked at No. 6 among Top 20 Global Biotech Employers by the Science Magazine

Biocon Unveils Biocon Academy - A Center of Excellence for Advanced Learning in Applied Biosciences

Biocon & Mylan received Indian Regulatory Approval for Trastuzumab for Treating Breast Cancer

Biocon and Quark Pharmaceuticals Collaborate to Develop Novel siRNA based Therapeutics

Biocon's ALZUMAb wins BioSpectrum BioPharma Product of the Year, 2013

Biocon Academy's Flagship Program in Collaboration with KGI Takes Off to a Flying Start


Biocon announced Positive Results from its Global Phase 3 study with Recombinant Human Insulin

GE Capital invests in fun88, Biocon's Research Services Subsidiary

Biocon announced Positive Efficacy Data from Phase 3 clinical study with its Novel Monoclonal Antibody, Itolizumab for Psoriasis

fun88 - a subsidiary of Biocon Group, in collaboration with Abbott, setup a dedicated Nutrition Research and Development Center at Biocon Park

Biocon announced positive results from its Phase 1 Comparative PK-PD Study with Biosimilar Insulin Glargine

Biocon: the only Asian Company to Feature in the Global Top 20 BioPharma Employers, by Science Magazine

Biocon enters into an agreement with Bristol-Myers Squibb for its IN-105, an Oral Insulin drug


Biocon divests its stake in its German subsidiary, AxiCorp GmbH, to the existing group of promoter shareholders, AxiCorp was the licensee for Biocon's biosimilar Insulin and Glargine in Germany and had the sole responsibility for commercializing these products. As a consequence of this divestment, these rights revert to Biocon.

Biocon announced project commencement for first high-end fun88官网 manufacturing and R&D facility in Bio-XCell, Malaysia

Biocon launched INSUPen®, a convenient and affordable reusable insulin delivery device.


Biocon explores investment in Malaysia in partnership with BiotechCorp

Biocon and Bayer join hands to create awareness for self monitoring for diabetics

fun88 and Endo Pharmaceuticals, USA  to  jointly discover and develop novel biological drug molecules to fight cancer

Biocon acquires stake of its Cuban partner CIMAB S.A. in their seven year old JV, Biocon fun88官网s Pvt. Ltd

Biocon and Optimer Pharmaceuticals announce manufacturing and supply agreement for a novel API, first-in-class anti-infective (C. difficile)

Biocon and the Center of Molecular Immunology (CIM), based in Havana, Cuba strengthen their existing research   partnership by joining forces for an integrated antibody program in immunology

Biocon announced a strategic foreign direct investment in Malaysia with the Malaysian Biotechnology Corporation SdnBhd (BiotechCorp)


Biocon's fun88 partners with Sapient Discovery to expand integrated drug discovery offerings

Biocon's fun88 and DuPont Crop Protection Forge Alliance Partnership

Bristol-Myers Squibb and Biocon's fun88 open new R&D Facility at Biocon Park

Biocon launched BASALOG - long lasting basal insulin for Type 1 & Type 2 Diabetics

Biocon inks partnership with ISB to launch the Biocon Cell for Innovation Management

Biocon announced Strategic Collaboration with Mylan to enter the Global Generic Biologics Market

Biocon Limited and Amylin Pharmaceuticals entered into a Global Development and Commercialization Agreement for a Novel Peptide Hybrid. The Program will focus on the potential treatment of diabetes.

Biocon and HCG group of hospitals join hands to fight against cervical


Biocon acquires a 78% stake in German pharmaceutical company, AxiCorp GmbH for a consideration of €30 Million

Biocon launched a Safety Device in the form of pre-filled syringes for two of its life saving products, GCSF (granulocyte-colony stimulating factor) and EPO (Erythropoietin) in collaboration with Safety Syringes Inc. ERYPRO Safe and NUFIL Safe are the first two drugs that will marketed using this novel device with other injectable products to follow in the future.

Biocon and Abraxis Bioscience launch ABRAXANE in India for treatment of Breast Cancer.

Biocon is ranked among the top 20 global biotechnology companies (Med Ad News).

Biocon is the 7th largest biotech employer in the world (Med Ad News).

Biocon announced the results of an ascending dose study on its oral insulin drug (IN-105) at the European Association for the Study of Diabetes (EASD) meeting in Rome.

NeoBiocon and Abraxis Bioscience launch Abraxane in The UAE for the treatment of Breast Cancer.


Biocon and Abu Dhabi based pharmaceutical company Neopharma sign an MOU to establish a JV to manufacture and market a range of fun88官网s for the GCC countries (Gulf Cooperation Council).

Biocon grants exclusive license to Ferozsons Laboratories Limited for marketing BIOMAb EGFR® in Pakistan.

Biocon announced the launch of its Nephrology Division and a comprehensive portfolio of renal therapy products.

fun88 enters into a research partnership with Bristol-Myers Squibb and completes the ground breaking ceremony of new research facility at Biocon Park.

Biocon signs Memorandum of Understanding with Deakin University, Australia. To establish Deakin Research Institute in Bangalore

Biocon divests enzymes division for USD 115 million to Novozymes. Biocon business portfolio to focus on fun88官网s

Biocon and Abraxis BioScience, announce an agreement wherein Abraxis will license the right to develop a biosimilar version of G-CSF (Granulocyte-Colony Stimulating Factor) in North America and the European Union.

Biocon and Neopharma sign an MoU to establish Neobiocon, a joint venture company in Dubai's biotechnology and research park, Dubiotech.

Biocon and Abraxis BioScience Inc., announce a licensing agreement for the commercialization of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in India.

Biocon presents the results of Phase 1 studies on its oral insulin product, IN-105 at the European Association for Study of Diabetes (EASD) meeting held at Amsterdam.


Biocon inaugurates Biocon fun88官网s, India's largest multi-product Biologics facility at Biocon Park

Biocon inaugurates Biocon Park, India's largest integrated biotechnology hub, comprising an integrated cluster of research laboratories and manufacturing facilities spread across 90 acres in KIADB (Karnataka Industrial Areas Development Board) industrial estate.

Biocon announced a licensing agreement with Bayer HealthCare (BHC) for the exclusive marketing and trademark rights for INSUGEN® for the Chinese market.

fun88 and Innate Pharmaceuticals AB, Umea, Sweden conclude a cooperation agreement to jointly develop, manufacture and market virulence blockers to counteract bacterial diarrhoeal disease.

Biocon launched India's first anti-cancer drug BIOMAb EGFR®.


Biocon signs a commercial agreement for supply of insulin API to Asia, Africa and the Middle East


Biocon creates a buzz in the stock market in March 2004 with its hugely successful IPO. Day 1 on the bourses closes with a market value of $1.11 billion, making Biocon only the second Indian company to cross the $1 billion mark on the first day of listing.

fun88 establishes new research centre

Biocon Limited, announced the launch of INSUGEN®, the new generation bio-insulin, manufactured in Asia's largest human insulin plant.

Biocon Limited and Vaccinex, Inc. announce a broad strategic partnership to discover and co-develop at least four therapeutic antibody products.


Biocon is the first company worldwide to develop human insulin on a Pichia expression system


Clinigene's clinical laboratory is the first in India to receive CAP accreditation


Biocon becomes the first Indian company to be approved by US FDA for the manufacture of lovastatin, a cholesterol-lowering molecule

Biocon's proprietary bioreactor, PlaFractor™ is granted a US 2001 and world-wide patent


Biocon commissions its first fully automated submerged fermentation plant to produce specialty pharmaceuticals

Biocon establishes Clinigene, India's first Clinical Research Organisation (CRO) to pursue clinical research and development


Unilever inks a deal with ICI to sell its specialty chemicals division of which Quest International is a part. Unilever agrees to sell its shareholding in Biocon to the Indian promoters. Biocon becomes an independent entity


Biocon spearheads initiatives in human healthcare through a dedicated manufacturing facility


The commercial success of Biocon's proprietary fermentation plant leads to a 3-fold expansion

Biocon leverages its technology platform to enter fun88官网s and statins


Biocon establishes fun88 International Pvt. Ltd. as a Custom research Company (CRC) to address the growing need for outsourced R&D in the pharmaceutical sector


Biocon's R&D and manufacturing facilities receive ISO 9001 certification from RWTUV, Germany


Biocon scales up its in-house research programme, based on a proprietary solid substrate fermentation technology, from pilot to plant level


Unilever plc. acquires Biocon Biochemicals Ltd. in Ireland and merges it with its subsidiary, Quest International

Biocon is the first Indian biotech company to receive US funding for proprietary technologies


Biocon is the first Indian company to manufacture and export enzymes to USA and Europe

November 29, 1978

Biocon’s Founding Day - the start of a biorevolution in India. Over the years, Biocon has evolved from an enzyme-manufacturing company into a fully integrated fun88官网 enterprise. Today, we leverage a formidable combination of proprietary fermentation technologies and research skills to develop affordable therapy for unmet medical needs

Biocon India is incorporated as a joint venture between Biocon Biochemicals Ltd. of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw


Biocon Fact Sheet


Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

  Report adverse event/side effects and product complaints    
  * Disclaimer            © 2018, Biocon. All Rights Reserved